Introduction {#s0010}
============

Nearly all mammalian cells express proteoglycans on their cell surface. The type of glycosaminoglycans (GAGs) attached to core proteins defines proteoglycans as heparan sulfate proteoglycans (HSPGs), chondroitin sulfate proteoglycans (CSPGs), dermatan sulfate proteoglycans (DSPGs), or keratan sulfate proteoglycans (KSPGs) ([@bb0305]). Some proteoglycans are hybrid proteoglycans carrying both heparan sulfate (HS) and chondroitin sulfate (CS) chains. Surface proteoglycans include the syndecan and glypican families with four and six members in mammals, respectively, CD44, betaglycan, NG2 (AN2 in mice, CSPG4 in humans), phosphacan, thrombomodulin, neuropilin-1, invariant chain, and α5β1 integrin ([@bb0305]). Studies on GAGs and proteoglycans date back to 1916 when heparin, a highly sulfated version of HS, was unexpectedly identified as a potent anticoagulant in liver extracts (thus, the name heparin) by a medical student who was trying to isolate a pro-coagulant molecule ([@bb0165]). HS was first considered as a contaminant in the heparin preparation, but was later distinguished from heparin in 1948 by the difference in the extent of sulfation and greater structural variability ([@bb0195]; [@bb0245]). For a long time, biological functions of proteoglycans were largely speculative and, in fact, most proteoglycans were thought to be specific to cartilage, functioning as cushions in joints for variable, compressive loads. Studies in the last several decades have revealed that surface proteoglycans are important modulators of many molecular interactions, including many relevant to lung biology.

Structure {#s0015}
=========

A proteoglycan consists of a core protein and one or several covalently attached GAG chains. GAGs are linear polysaccharides comprised of repeating disaccharide units that are defined by the composition and chemical linkage of the amino sugar and uronic acid monosaccharides in the disaccharide unit ([@bb0215]; [@bb0135]). The signature disaccharide repeat of an HS/heparin polysaccharide is GlcUAβ1-4GlcNAcα1-4, chondroitin sulfate (CS) is GlcUAβ1-3GalNAcβ1-4, dermatan sulfate (DS) is IdoUAβ1-3GalNAcβ1-4, keratan sulfate (KS) is Galβ1-4GalNAcβ1-3, and hyaluronan (HA) is GlcUAβ1-3GlcNAcβ1-4 ([@bb0215]; [@bb0110]; [@bb0130]; [@bb0365]). Except for HA, all GAGs are attached to core proteins and exist as proteoglycans in vivo. GAGs are attached to and polymerized on certain Ser residues of a Ser-Gly dipeptide sequence often repeated two or more times. The unmodified polymerized GAGs are modified in the Golgi by several sulfation and epimerization reactions that are catalyzed by distinct enzymes. Because the polymerization and modification reactions do not go to completion, the biosynthetic process generates an exceptionally diverse array of GAG structure, both in length and extent of modification. For example, HS, the most structurally heterogeneous GAG, varies in length from 20 to 150 disaccharides (\~ 20--150 nm) with cell type and core protein ([@bb0330]). However, a mere HS decasaccharide can potentially assume over 10^6^ distinct sequences, which is already in vast excess of the estimated gene products that the whole human genome can generate. This enormous structural diversity largely explains why and how HS binds to so many proteins.

Surface proteoglycans harbor HS, CS, DS, or a combination of HS and CS. Core proteins of syndecans ([@bb0050]; [@bb0290]), NG2 ([@bb0350]), CD44 ([@bb0145]), betaglycan ([@bb0180]), phosphacan ([@bb0255]), and thrombomodulin ([@bb0310]) are type I transmembrane proteins ([@bb0090]), whereas core proteins of glypicans are attached to the surface through a glycosylphosphatidylinositol (GPI) anchor ([@bb0125]; [@bb0120]; [@bb0050]; [@bb0290]). As shown in [Fig. 1](#f0010){ref-type="fig"} , these core proteins have distinct structural designs and GAG attachment sites. For example, syndecan core proteins contain an extracellular domain extended in conformation due to a high Pro content, whereas glypican extracellular domains are globular because they contain 14 Cys residues, conserved across all six glypicans, that form intramolecular disulfide bonds. HS chains are attached distal to the plasma membrane on all syndecans and CS chains are also attached proximal to the cell surface on some syndecans (e.g., syndecan-1). GAG attachment sites in NG2 (CS) and CD44 (HS/CS) are located in the middle portion of the core protein, whereas those of glypicans (HS), thrombomodulin (CS), and betaglycan (HS/CS) are proximal to the cell surface. The short cytoplasmic domain of syndecans contains several signaling and scaffolding motifs, such as three highly conserved Tyr, one highly conserved Ser, and a C-terminal PDZ binding domain ([@bb0050]). The NG2 cytoplasmic domain also contains a PDZ binding domain and several Thr residues that may be phosphorylated ([@bb0350]). Similarly, cytoplasmic domain of betaglycan contains a PDZ binding motif that interacts with β-arrestin ([@bb0055]), in addition to Ser- and Thr-rich regions that may be modified by members of the protein kinase C (PKC) family ([@bb0250]). The CD44 cytoplasmic domain contains an ezrin, radixin, moesin (ERM) motif that may link surface CD44 to the actin cytoskeleton. The cytoplasmic domain of thrombomodulin also contains an ezrin binding site which, through interactions with ezrin and actin, is thought to regulate cell morphology and migration ([@bb0170]).Fig. 1Schematic depiction of cell surface HSPGs.Fig. 1

Regulation of Production and Activity {#s0020}
=====================================

The temporal and spatial expression patterns of surface proteoglycans are highly regulated. For example, syndecan-1 is first detected at the 4-cell stage in mouse embryos, suggesting that its expression is zygotically activated ([@bb0045]). In adult lung, syndecan-1 is the predominant HSPG expressed on the basolateral surface of airway and alveolar epithelia ([@bb0220]). Lung epithelia also express syndecan-4, although its expression is much lower than that of syndecan-1. Several inflammatory mediators (e.g., TGFβ, antimicrobial peptides) and pathological conditions (e.g., cancer, myocardial infarction) regulate the expression of surface proteoglycans at the transcriptional and post-transcriptional level ([@bb0045], [@bb0050]; [@bb0360]; [@bb0090]). Furthermore, surface expression of syndecans and CD44 can be regulated by a proteolytic cleavage mechanism called ectodomain shedding ([@bb0155]; [@bb0240]; [@bb0030]). Ectodomain shedding is of paramount importance to proteoglycan biology because it both rapidly changes the surface phenotype of affected cells by reducing the amount of surface GAGs and generates soluble proteoglycan ectodomains replete with all their GAGs that can function as autocrine or paracrine effectors. Glypicans are also released from the cell surface by cleavage of their GPI anchor by phopholipases in vitro ([@bb0125]; [@bb0120]; [@bb0050]), suggesting that glypicans also function as soluble molecules in vivo. Most of the other surface proteoglycans are also found in soluble form, but how they are released from the cell surface is not known. The activity of proteoglycans is largely mediated by the sulfate motifs elaborated in the attached GAG chains ([@bb0135]). Thus, mechanisms that regulate the sulfation patterns have a direct effect on proteoglycan functions. For example, the HS sulfatases, SULF1 and SULF2, remove 6-*O*-sulfates from HS ([@bb0095]) and inhibit cellular responses to FGF and FGF-induced angiogenesis ([@bb0380]).

Biological Functions {#s0025}
====================

Surface proteoglycans, especially those elaborating the highly structurally diverse HS chains, bind and regulate a wide variety of biological molecules through their HS chains. The list includes ECM components, growth factors, chemokines, proteinases, antimicrobial peptides, and many more ([@bb0050]; [@bb0290]; [@bb0315]; [@bb0090]). Surface proteoglycans can serve as primary receptors for some ligands (e.g., lipoproteins), but in most cases, surface proteoglycans function as coreceptors that capture ligands and catalyze the encounter between ligands and their respective signaling receptors in a multi-receptor complex. Surface proteoglycans can also regulate receptor-ligand interactions by affecting the stability, conformation, oligomerization state, and spatial distribution of either ligand or signaling receptor ([@bb0330]). Furthermore, binding of chemokines and some morphogens to surface proteoglycans generates a directional gradient that guides cell migration ([@bb0140]; [@bb0390]). In addition, ectodomain shedding generates soluble forms of the surface proteoglycans that show functions similar to or distinct from their immobilized counterparts.

The biological significance and relevance of surface proteoglycan functions is perhaps best exemplified by phenotypes of mice made null for the various biosynthetic enzyme and core protein genes. For example, mice lacking *N*-deacetylase/*N*-sulfotransferase-1 (*Ndst1*) ([@bb0325]; [@bb0115]) or C5 epimerase ([@bb0225]), enzymes required for the synthesis of sulfated HS, die shortly after birth due to various developmental abnormalities, including lung defects. The *Ndst1* null mice, in particular, show an incomplete maturation of type II pneumocytes. CD44 null mice show defects in the tissue distribution of myeloid progenitors ([@bb0335]). Glypican-3 null mice show phenotypes resembling Simpson Golabi Behmel Syndrome, a human overgrowth disorder, and these mice also show abnormal lung development ([@bb0065]; [@bb0070]). Glypican-6 mice display embryonic lethality due to various development defects that are apparently caused by deficient Hedgehog signaling which glypicans negatively regulate ([@bb0075]). Mutations in glypican-4 cause Keipert syndrome in humans, and while some features of this genetic disease are recapitulated in glypican-4 null mice, the phenotypes are substantially milder than in the human disease ([@bb0015]). Similarly, syndecan-2 null mice are viable with no gross abnormalities, although close examination revealed developmental abnormalities in retinal blood vessels ([@bb0085]). No apparent major developmental abnormalities have so far been found in mice that lack syndecan-1 ([@bb0010]; [@bb0295]), -3 ([@bb0200]) or -4 ([@bb0105]). However, syndecan-1 and -4 null mice show abnormal phenotypes when subjected to experimental models of tissue injury and infection as described below.

Surface Proteoglycans in Respiratory Diseases {#s0030}
=============================================

Several lines of evidence indicate that surface proteoglycans are central players in the pathogenesis of respiratory diseases ([Fig. 2](#f0015){ref-type="fig"} ). In general, low expression of surface proteoglycans is associated with a poor prognosis in lung and other cancers. For example, syndecan-1 is expressed by most types of lung cancer cells ([@bb0210]), but expression is generally reduced in lung cancers ([@bb0270]), and higher expression of syndecan-1 is associated with a better prognosis in non-small cell lung carcinomas, including adenocarcinoma and squamous cell carcinoma ([@bb0340]; [@bb0020]). Similarly, glypican-3 expression is decreased in lung adenocarcinoma ([@bb0205]), suggesting that both syndecan-1 and glypican-3 are potential lung tumor suppressors. The biological basis for the association between surface proteoglycan expression and lung cancer has yet to be clearly defined, but it is speculated that normal expression of surface proteoglycans is required to suppress cellular activities central to cancer progression, such as abnormal cell migration, proliferation, and differentiation. By contrast, syndecan-2 is overexpressed in lung adenocarcinoma and is thought to potentiate the invasiveness of lung adenocarcinoma cells ([@bb0375]). Because most HSPGs are thought to function through their HS chains, the opposite functions of surface HSPGs may suggest that the fine structure of HS is different among these proteoglycans. Alternately, their pro- or anti-tumor functions may be mediated by their core proteins or they may harbor other GAG chains under tumorigenic conditions. The tetrasaccharide link domain that is *O*-linked to Ser residues of proteoglycan core proteins primes synthesis of all GAGs except for HA. Thus, in principle, GAG attachment may be regulated by the transformation state of the cell and the microenvironment in which the transformed cell resides. In fact, CS/DS levels are decreased in lung cancer tissues ([@bb0235]), which may suggest a shift in the expression of GAGs or downregulation of CSPG and DSPG core proteins. Furthermore, high levels of soluble syndecan-1 ectodomains are associated with a poor outcome in lung carcinomas ([@bb0190]), suggesting that aberrant activation of syndecan-1 shedding may promote lung cancer progression.Fig. 2Major functions of epithelial cell surface HSPGs in lung disease.Fig. 2

Lung inflammation is exacerbated in CD44 null mice instilled intratracheally with bleomycin ([@bb0355]) and in syndecan-1 null mice instilled intranasally with allergens ([@bb0385]), suggesting that these surface proteoglycans mitigate inflammatory responses. In the mouse model of interstitial pneumonia, CD44 is required to clear apoptotic neutrophils and accumulated HA fragments at sites of tissue injury, and to assure the correct activation of TGFβ1. In the mouse model of allergic lung inflammation, syndecan-1 attenuates inflammation by inhibiting the recruitment of Th2 cells to the lung, a central process in asthma pathogenesis. Here, syndecan-1 shedding by airway epithelial cells is activated by allergen challenge and shed ectodomains attenuate lung inflammation by binding and inhibiting the CC chemokines CCL7, CCL11, CCL17 through their HS chains. Syndecan-1 shedding has also been found to modulate lung inflammation in bleomycin-induced acute lung injury ([@bb0220]). Upon injury, newly synthesized KC (CXCL1, functional homologue of human IL-8) binds to syndecan-1 HS on alveolar epithelial cells and the syndecan-1/KC complex is shed by MMP-7. This process generates a KC gradient that guides the transepithelial migration of neutrophils into the alveolar compartment. On the other hand, when the inflammatory stimulus is administered systemically, syndecan-1 shedding removes chemokines tethered to endothelial cells, dissipates chemokine gradients, and facilitates the resolution of neutrophilic inflammation. Consistent with this mechanism, syndecan-1 null mice are hypersusceptible to endotoxemia-induced acute lung injury when LPS is injected intravenously ([@bb0150]). Syndecan-1 also attenuates lung injury in influenza infection by stimulating pro-survival signaling and suppressing epithelial apoptosis ([@bb0060]), but it is not known if the cell surface or shed form of syndecan-1 mediates the observed protection.

Similar to the different functions in lung cancer, syndecans apparently have opposing functions in lung fibrosis. Syndecan-2 inhibits fibroblast activation via its interaction with CD148 and attenuates radiation-induced lung fibrosis ([@bb0370]). Similarly, syndecan-4 binding to CXCL10 inhibits chemokine-mediated fibroblast recruitment and mitigates lung fibrosis. Consistent with these mechanisms, syndecan-4 null mice are hypersusceptible to bleomycin-induced lung fibrosis ([@bb0185]). In contrast, syndecan-1 promotes lung fibrosis by augmenting TGFβ and Wnt signaling ([@bb0280]). The reason for these different phenotypes are not understood, but because syndecan-1 is expressed by lung epithelial cells, whereas syndecan-2 and syndecan-4 are expressed primarily by lung endothelial cells and fibroblasts, respectively, the cell-specific expression pattern and level of expression are thought to underlie how syndecans function distinctly and specifically in pulmonary fibrosis. Similar to the role of syndecan-1, inhibition or ablation of CD44 inhibits fibroblast invasion and myofibroblast activation, and attenuates bleomycin-induced lung fibrosis, indicating that CD44 promotes the progression of disease ([@bb0230]). However, it is not know if the proteoglycan isoform of CD44 mediates these effects. Similarly, while NG2 is a biomarker for pericytes ([@bb0345]), which are mesenchymal cells that promote lung fibrosis when activated ([@bb0035]; [@bb0175]), the role of NG2 in the pro-fibrotic activities of pericytes is not known.

In lung infection, many bacterial and viral pathogens exploit surface proteoglycans as attachment and invasion receptors. Respiratory pathogens, such as *Mycobacterium* spp., *Bordetella pertussis*, *Haemophilus influenzae*, SARS-CoV, metapneumovirus, parainfluenza virus and respiratory syncytial virus, bind to the HS moiety of surface HSPGs for their attachment and invasion ([@bb0040]; [@bb0025]). For example, syndecan-1 and -4 have been shown to directly mediate *M. tuberculosis* entry in human and mouse lung epithelial cells ([@bb0395]), consistent with the finding that *M. tuberculosis* uses a heparin-binding hemagglutinin to enter alveolar epithelial cells ([@bb0260]; [@bb0320]). HSPGs can also serve as coreceptors for respiratory pathogens. SARS-CoV uses ACE2 as its entry receptor ([@bb0100]), but at least in cell-based assays, ACE2 expression alone is not sufficient for cellular infection. Instead, SARS-CoV initially binds to surface HSPGs and this interaction is thought to increase virus density at the cell surface to facilitate the interaction of SARS-CoV with ACE2 for viral entry ([@bb0265]).

Several respiratory bacterial pathogens, such as *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Streptococcus pneumoniae*, take advantage of syndecan-1 shedding in lung epithelial cells to promote their pathogenesis. Syndecan-1 shedding is specifically activated by secreted virulence factors: LasA for *P. aeruginosa* ([@bb0285]), α-toxin and β-toxin for *S. aureus* ([@bb0300]), and ZmpC for *S. pneumoniae* ([@bb0080]), and the shed ectodomains inhibit innate defense factors (e.g., antimicrobial peptides, collectins) through their HS chains ([@bb0295]; [@bb0160]). ZmpC directly cleaves syndecan-1 ectodomains, whereas LasA and α-toxin stimulate the host cell\'s shedding mechanism, suggesting that shedding activation is receptor mediated. Syndecan-1 ablation causes a gain of function where syndecan-1 null mice are significantly less susceptible to intranasal *P. aeruginosa* lung infection, and wild type mice are protected from infection by intranasal administration of inhibitors of syndecan-1 shedding and HS ([@bb0295]), indicating that activation of syndecan-1 shedding is an important virulence activity shared by several respiratory bacterial pathogens. Interestingly, syndecan-4 null mice are more susceptible to pneumococcal pneumonia ([@bb0275]). Because syndecan-4 ectodomains are not shed by pneumococcus, perhaps surface syndecan-4 has functions that attenuate pneumococcal colonization in the lung. Regardless, these studies highlight the functional complexity of surface proteoglycans. Furthermore, these studies underscore the importance of surface proteoglycans in the pathogenesis of several major respiratory diseases. Additional studies directed at further defining the molecular and cellular mechanisms of surface proteoglycans in lung disease should lead to a better understanding of how fundamental functions of these complex glycoproteins influence the onset, progression, and outcome of lung disorders.
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